GE HealthCare and Mayo Clinic Launch MI-BET Study to Advance Personalized Radioligand Therapy for Advanced Prostate Cancer GE HealthCare and Mayo Clinic have announced the launch of the Molecular Imaging Biomarker-Based End of Therapy (MI-BET) research collaboration, a pioneering clinical…
Octave MSDA Test Proven Effective in Identifying True MS Relapse Octave Bioscience, a commercial-stage precision neurology company focused on advancing personalized care for multiple sclerosis (MS) and other neurodegenerative disorders, has announced the publication of new independent research demonstrating the…
Catalent and Nanoscope Therapeutics Expand Partnership to Advance Commercial Readiness of Vision-Restoring Gene Therapy MCO-010 Catalent, Inc., a global leader in development, manufacturing, packaging, and supply solutions for the pharmaceutical and biotechnology industries, has expanded its strategic partnership with Nanoscope…
Incyte Completes $1.25 Billion Acquisition of Vega Therapeutics, Expanding Hematology Portfolio with Late-Stage von Willebrand Disease Therapy VGA039 Incyte has announced the successful completion of its acquisition of Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics LLC, marking…
Signatera™ MRD Test Predicts Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer Natera, Inc., a global leader in cell-free DNA testing and precision medicine, has announced the publication of new clinical data in JAMA Oncology demonstrating the potential…
Arima Genomics Partners with Active Motif to Expand Access to Hi-C Research Technologies While Accelerating Clinical Cancer Diagnostics Strategy Arima Genomics, Inc., a biotechnology company focused on advancing precision oncology through innovative cancer diagnostics, has announced a new strategic distribution…
US Heart and Vascular Expands Georgia Presence Through Partnerships with Cardiovascular Clinic of North Georgia and Cardiology of Atlanta US Heart and Vascular, a national provider of administrative and operational support services for independent cardiovascular physician practices, has announced strategic…
Arcturus Therapeutics and Thermo Fisher Scientific Form Strategic Collaboration to Advance ARCT-032 for Cystic Fibrosis Through Phase 3 Development and Potential Commercialization Arcturus Therapeutics Holdings Inc., a clinical-stage messenger RNA (mRNA) medicines company focused on developing innovative therapies for liver…
Azalea Vision Secures Up to €7.5 Million from European Innovation Council to Advance Smart Contact Lens Platform Toward Clinical Development Belgian health technology innovator Azalea Vision has secured a major boost for the development of its pioneering smart contact lens…
Colossal Foundation and University of Tasmania Launch Multi-Pronged Initiative to Combat Deadly Tasmanian Devil Facial Tumour Disease The Colossal Foundation, the nonprofit conservation organization established by Colossal Biosciences, has announced a strategic partnership with the University of Tasmania to accelerate…
Samsung Bioepis Reports Positive Phase 1 and Phase 3 Results for SB27, Its Proposed Pembrolizumab Biosimilar Samsung Bioepis Co., Ltd. has announced encouraging topline results from its Phase 1 and Phase 3 clinical development program for SB27, the company’s proposed…
Genentech’s Enspryng Receives FDA Priority Review for Thyroid Eye Disease, Advancing a Potential New Treatment Option Genentech, a member of the Roche Group, has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental Biologics…